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Pyrazinoic acid, the active form of the first-line antituberculosis drug pyrazinamide, decreased the proton
motive force and respiratory ATP synthesis rates in subcellular mycobacterial membrane assays. Pyrazinoic
acid also significantly lowered cellular ATP levels in Mycobacterium bovis BCG. These results indicate that the
predominant mechanism of killing by this drug may operate by depletion of cellular ATP reserves.
Shortening tuberculosis treatment duration is a key objective
in order to reduce noncompliance and to combat recently
emerging multidrug-resistant strains of Mycobacterium tuber-
culosis (6, 19, 36). Pyrazinamide (PZA), an important first-line
drug employed in tuberculosis chemotherapy, played a key role
in shortening the duration of tuberculosis treatment from 9
months to 6 months (22). PZA is a sterilizing drug that effi-
ciently kills populations of Mycobacterium tuberculosis residing
in acidic environments, as found during active inflammation (1,
7, 10, 11, 20, 21, 28, 32). Despite the importance of PZA, no
cellular target proteins have been clearly identified (4, 23, 30,
41), and its mechanism of action is probably the least under-
stood among all first- and second-line antituberculosis drugs. A
better understanding of PZA action may help in development
of new drugs to further shorten tuberculosis treatment.
PZA constitutes a prodrug that is hydrolyzed in the myco-
bacterial cell by pyrazinamidase to yield the active entity pyr-
azinoic acid (POA) (15, 16). According to the hypothesis put
forward by Zhang and colleagues, POA, a weak acid (pKa, 2.9),
acts as an uncoupling agent by breaking down the bacterial
membrane potential (39, 40). POA in its unprotonated form
can leave the cell by means of an unknown efflux system (37,
40), take up a proton in the acidic environment, and enter the
mycobacterial cell again in its protonated, less polar form (39).
The resultant decrease in proton motive force then blocks,
among other processes, uptake of metabolites required for
growth (40). However, it is not known whether the decreased
membrane potential observed for PZA in whole mycobacterial
cells (40) is due to the postulated uncoupling effect or indi-
rectly caused by interference of PZA or POA with other cel-
lular targets. Moreover, the impact of POA on respiratory
ATP synthesis and on cellular ATP levels has not been inves-
tigated. In the present study, we used subcellular and cellular
assays to address these open issues. We used M. bovis BCG,
which is resistant to PZA due to mutations in pyrazinamidase
(16, 29, 30) but is fully susceptible to POA (15, 31, 37), as a
model system.
POA directly interferes with the proton motive force. We
isolated membrane vesicles from M. bovis BCG as previously
reported (9). In this subcellular system, the cytosolic fraction is
removed, allowing a more specific investigation of drug action
directed to membrane components (8, 9). First we determined
whether pyrazinoic acid (POA) directly interferes with the
proton motive force. The proton motive force was moni-
tored with the ACMA (9-amino-6-chloro-2-methoxyacridine)
quenching method as described previously (9). Addition of
succinate caused fluorescence quenching, which was eased
upon addition of an uncoupler (SF6847), proving that the
quenching was caused by a proton motive force across the
membrane (Fig. 1). In the presence of POA, the proton motive
force decreased in a dose-dependent manner (Fig. 1). This
effect was more pronounced at pH 5.5 than at pH 6.5 (Fig. 1).
The POA concentrations needed to significantly decrease the
proton motive force were comparable to values reported ear-
lier for M. tuberculosis at the whole-cell level (40). This result
shows that POA directly interferes with membrane energetics.
POA decreases rates of respiratory ATP synthesis. Next, we
investigated the extent to which POA, by decreasing the proton
motive force, interferes with respiratory ATP production.
Rates of ATP synthesis by the mycobacterial membranes were
determined as described previously (8, 9). As depicted in Fig.
2, POA inhibited ATP synthesis in a dose-dependent manner.
The affinity for POA significantly decreased at higher pH, with
a 50% inhibitory concentration (IC50) value of 200 g/ml at pH
5.5 compared with 850 g/ml at pH 6.5 (Fig. 2, closed bars).
This result is consistent with the enhanced killing previously
observed at acidic pH for PZA in vivo and for POA in vitro (38,
40). As shown by the results of a control experiment, only a
minor effect was observed for PZA, with IC50s exceeding 2,000
g/ml at both pH values tested (Fig. 2, open bars). These
results strongly suggest that POA is the active entity that di-
minishes rates of ATP synthesis. By interfering both with up-
* Corresponding author. Mailing address: Department of Molecular
Cell Biology, Faculty of Earth and Life Sciences, VU University Am-
sterdam, De Boelelaan 1085, 1081 HV Amsterdam, The Netherlands.
Phone: 31(0)205986991. Fax: 31(0)205987136. E-mail: dirk.bald@falw
.vu.nl.
 Published ahead of print on 29 August 2011.
† The authors have paid a fee to allow immediate free access to
this article.
5354
take of metabolites as reported earlier (40) and with respira-
tory ATP synthesis as shown here, POA thus exerts at least a
dual action, which potentially renders it an exceptionally pow-
erful drug. This unusual property of POA may hold for bacte-
ria under conditions of a low energy supply in particular (12,
34) and may in part explain why pyrazinamide appears to
constitute an essential component of antituberculosis drug reg-
imens.
POA decreases cellular ATP levels. We investigated the
impact of ATP synthesis inhibition by POA on cellular ATP
levels. Addition of POA to M. bovis BCG grown in liquid
culture significantly decreased cellular ATP levels in both a
time-dependent and a dose-dependent manner (Fig. 3). The
concentrations of POA needed to reduce cellular ATP levels
correlate well with those required for ATP synthesis inhibition;
e.g., 800 g/ml POA (the IC50 in the ATP synthesis assay)
decreased cellular ATP levels by 40% after 1 day and 60%
after 6 days. In control experiments, PZA did not significantly
change ATP levels. These results suggest that POA interfer-
ence with respiratory ATP synthesis has a significant impact on
cellular ATP levels and may be the cause of bacterial killing.
PZA and POA share several interesting characteristics with
a new series of ATP synthesis inhibitors, the diarylquinolines
(2, 5, 9a), as follows. Both drugs show delayed action in vitro
and in vivo, with time-dependent killing observed only from
days 3 and 4 on (27, 40). Moreover, both drugs display a
particularly strong effect on mycobacteria under (semi-) dor-
mant conditions (10, 18, 26, 33, 38). Finally, in similarity to our
data reported here for POA, TMC207 reduces cellular ATP
levels (17, 18, 26). Based on the similarities in activity signa-
tures, we suggest that the two drugs share the same predomi-
nant mechanism of killing, i.e., depleting the cellular ATP
pool. It needs to be determined to what extent alternative
targets are involved and to what extent they contribute to the
pronounced bactericidal action of pyrazinamide.
The chain of events leading from (too) low ATP levels to
FIG. 1. Pyrazinoic acid decreases the proton motive force in a subcellular assay. The proton motive force in membrane vesicles from M. bovis
BCG was monitored in the presence of pyrazinoic acid at the indicated concentrations (measured in micrograms per milliliter) by quenching of
ACMA as a fluorescence indicator at pH 6.5 (A) and pH 5.5 (B). Succinate and the uncoupler SF6847 were added to establish and collapse the
proton motive force at the time points indicated by the arrows. Each experiment was carried out in triplicate; representative results are shown.
FIG. 2. Pyrazinoic acid inhibits ATP synthesis. ATP synthesis activity by membrane vesicles was determined using the glucose-6-phosphate
method for quantification of the ATP produced (9). The reaction was carried out in the presence of the indicated concentrations (Con) of
pyrazinoic acid (closed bars) or pyrazinamide (open bars) at pH 6.5 (A) or pH 5.5 (B). Each graph shows the mean values and standard deviations
of the results of three independent experiments.
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bacterial killing is presumably complex (14, 24), and the factors
involved need to be elucidated. Drugs interfering with cellular
energy pools appear to be very powerful, especially against
dormant bacteria. Membrane function and respiratory ATP
synthesis may constitute examples of a new generation of an-
tibiotic targets for treatment of persistent infections (3, 13, 19,
40). The subcellular membrane assay for characterization of
pyrazinoic acid described here can be applied for screening
and characterization of this new generation of compounds
targeting respiratory ATP production.
P.L. gratefully acknowledges financial support from the Chinese
Scholarship Council. A.C.H. and D.B. gratefully acknowledge financial
support from the Nederlandse Organisatie voor Wetenschappelijk
Onderzoek (NWO-ECHO grant 700.55.017).
We thank B. Appelmelk and W. Bitter (Medical Microbiology &
Infection Control, VU University Medical Center) and M. Braster
(Molecular Cell Physiology, VU University) for assistance with bacte-
rial culture and luminescence measurements, respectively.
ADDENDUM IN PROOF
While this paper was in press, W. Shi et al. (Science 333:
1630–1632, 2011) reported the ribosomal protein RpsA as an
additional target of pyrazinamide. The relative importance of
the respective targets for bacterial killing needs to be investi-
gated.
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